Understanding the Connection Between Pulmonary Hypertension & Scleroderma, live webinar by the Canadian Pulmonary Hypertension Association PHA Canada, January 13, 2025

Join Dr. Nathan Hambly, a respirologist at the Firestone Institute for Respiratory Health at St. Joseph’s Healthcare, Hamilton, Canada, as he explores why pulmonary arterial hypertension happens in scleroderma, how to spot the signs early, and what care options exist today. 🗓️ January 13 | 🕐 1:30 pm EST | 💻 Online🎙️ Hosted in partnership […]

Understanding the Connection Between Pulmonary Hypertension & Scleroderma, live webinar by the Canadian Pulmonary Hypertension Association PHA Canada, January 13, 2025 Read Post »

Join the US Pulmonary Hypertension Association and US National Scleroderma Foundation for the “Managing Scleroderma and Pulmonary Arterial Hypertension” live webinar Friday, Sept. 20, 2024

The Pulmonary Hypertension Association in the US in collaboration with the National Scleroderma Foundation is organising a live webinar on September 20, 2024 at 2 p.m. EDT/6 p.m. UTC on “Managing Scleroderma and Pulmonary Arterial Hypertension”. Scleroderma is an autoimmune disease in which the immune system attacks various organs and tissues, including the lungs, kidneys,

Join the US Pulmonary Hypertension Association and US National Scleroderma Foundation for the “Managing Scleroderma and Pulmonary Arterial Hypertension” live webinar Friday, Sept. 20, 2024 Read Post »

Recent study suggests that resistin could be a key biomarker and therapeutic target in pulmonary arterial hypertension, “Respiratory Research”, June 6, 2024

The findings of study which aimed to evaluate the potential for using resistin as a genetic and biological marker for disease severity and survival in pulmonary arterial hypertension were published on June 6, 2024 in “Pulmonary Research”. Resistin is an adipose-derived hormone (similar to a cytokine). The researchers collected biospecimens, clinical, and genetic data for 1.121 adults

Recent study suggests that resistin could be a key biomarker and therapeutic target in pulmonary arterial hypertension, “Respiratory Research”, June 6, 2024 Read Post »

TRANSLATE »
Scroll to Top